Back to News
Market Impact: 0.45
Ultragenyx Phase 3 Aspire Trial Of Apazurersen Misses Key Goals In Angelman Syndrome; Shares Plunge
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsAnalyst Insights
Ultragenyx (RARE) reported that its Phase 3 Aspire study of apazutersen (GTX-102) in Angelman syndrome did not meet the primary or key secondary endpoints. The clinical readout is a material setback for the program’s efficacy case and increases uncertainty around future development and potential commercialization.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
RARE-0.85
More News
- Nvidia CEO Jensen Huang emerges as Trump's top ally in AI safety debate
- GE Aerospace Goes Vertical (Integration)
- Who’s who in Fed’s September 2026 dot plot?
- Williams-Sonoma's stock has soared in a sluggish housing market. Here's how it won over Wall Street
- DPM Metals Expands Brevene Porphyry South Discovery with New High-Grade Intercepts
- Budget airline king Bill Franke warms to first-class seats and premium upgrades